120
Participants
Start Date
August 31, 2005
Primary Completion Date
October 31, 2008
Study Completion Date
May 31, 2009
tgAAC94 gene therapy vector
Single Dose 1x10\^11 DRP/mL
tgAAC94 gene therapy vector
Second dose of 1x10\^11 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
tgAAC94 placebo
placebo
tgAAC94 gene therapy vector
Single Dose 1x10\^12 DRP/mL tgAAC94
tgAAC94 gene therapy vector
Second dose of 1x10\^12 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
tgAAC94 gene therapy vector
Single Dose 1x10\^13 DRP/mL tgAAC94
tgAAC94 gene therapy vector
Second dose of 1x10\^13 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
United Medical Associates, Johnson City
Altoona Center for Clinical Research, Duncansville
Rheumatic Disease Associates, Willow Grove
Arthritis and Osteoporosis Center of Maryland, Frederick
RASF-Clinical Research Center, Boca Raton
Ocala Rheumatology Research Center, Ocala
Radiant Research Stuart, Stuart
Northwestern Center for Clinical Research, Chicago
The Arthritis Center, Springfield
Bone and Joint Hospital Research Dept., Oklahoma City
Arthritis Consultation Center, Dallas
Metroplex Clinical Research Center, Dallas
Radiant Research San Antonio Northeast, San Antonio
Austin Rheumatology Research, Austin
Denver Arthritis Research Center, Denver
Coeur d'Alene Arthritis Clinic, Coeur d'Alene
Sun Valley Arthritis Center, Glendale
Catalina Pointe Clinical Research, Inc, Tuscon
Arthritis Center of Reno, Reno
Boling Clinical Trials, Upland
Desert Medical Advances, Palm Desert
Seattle Rheumatology Associates, PLLC, Seattle
Targeted Genetics Corporation
INDUSTRY